Canadian Pacific Kansas City Limited Common Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $84.41 (market cap $73.98B), while State Street SPDR S&P Biotech ETF trades at $153.61 (market cap $10.11B). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 7.3× State Street SPDR S&P Biotech ETF's market cap, and Canadian Pacific Kansas City Limited Common Shares pays a 0.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| CP | XBI | |
|---|---|---|
Market Cap | $73.98B | $10.11B |
Volume | 1,669,828 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $96.69 | $169.55 |
52-Week Low | $68.88 | $104.99 |
Enterprise Value | $91.36B | — |
Dividend Yield | 0.9% | — |
Typical Hold Time | — | 37 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →